About us
Platforms
Pipelines
Facilities
Business
News
Contact us
KR
▼
01
About us
Spin off
History
Collaboration
CI
Loacation
02
Platforms
Ocular Implants
Microarray Patches
03
Pipelines
SMO Series
SMM Series
SMZ Series
04
Facilities
SMO Line
SMM Line
Sites
05
Business
Business Model
CDMO Business
06
News
Notice
IR
PR
07
Contact us
call@sminnovation.com
Home > Pipelines > SMO Series
SMO Series
SMO
SMO-IVT1
SMO-ICL1
SMO-IVT1 Information
Indication
Macular Edema
Active Ingredient
Dexamethasone 700 mcg
Implant Size
0.46 X 6 mm
Administration
Intravitreal Injection
Milestones
* SMO-IVT1 launch schedule is subject to change depending on the patent situation in each country
CEO : Jinha Park
Company : SANGMYUNG innovation Co., Ltd.
T : +82 2 3489 6100
Head Office : 2-27, Yeongmun-ro, Cheoin-gu, Yongin-si, Gyeonggi-do, Republic of Korea
Branch Office : 42, Seocho-daero 52-gil, Seocho-gu, Seoul, Republic of Korea
Privacy Policy
Copyright © SANGMYUNG innovation